Lewy Body Dementia Treatment Market: Innovative Trends Implemented by Manufacturers Steering Growth until 2028 | Key Players are Sumitomo Dainippon Pharma Co. Ltd., Jazz Pharmaceuticals Inc., etc.

As per the current market trends and the promising nature of the lewy body dementia treatment market, it can be estimated that the future holds positive outcomes. In order to provide a deep insight about the concerned market, FACT.MR would be publishing a resourceful analysis that will enclose knowledge about the lewy body dementia treatment market growth, revenue and opportunity status. Readers will be offered the privilege to decode various facets of the market during 2018-2028, together with the active access to secondary and primary research methodology. Furthermore, various segments of the market associated to product, application, end-user etc., would also be present in this intelligent research report.

To Get a Free Sample Copy of this Report, Visit here – https://www.factmr.com/connectus/sample?flag=S&rep_id=1154

Key Insights- Lewy Body Dementia Treatment Market

Global sales of lewy body dementia treatment were valued at over US$ 3,500 Mn in 2018, in line with wide-spread prevalence of lewy body dementia and subsequent need for effective treatment.
Cholinesterase inhibitors, valued at over US$ 2,100 Mn in 2018, will continue to remain the most lucrative category, followed by antipsychotic drugs. The minimal side effects associated with these two drug types are among the key reasons fuelling demand for these products.
North America will remain the largest market for lewy body dementia treatment in 2019 and beyond, owing to appropriate dementia drug regulations and superior healthcare infrastructure in the region.
East Asia is anticipated to emerge as the fastest-growing market for lewy body dementia treatment, as China and India spearhead demand with an ever-growing geriatric population.
 

Key Growth Drivers - Lewy Body Dementia Treatment Market 

 

Government initiatives aimed at creating awareness about lewy body dementia treatment are likely to uphold growth of the market. For instance, the US has signed into a law the BOLD Infrastructure for Alzheimer’s Act, an initiative aimed at forming a public health model against Alzheimer’s disease and other dementias. The law would sanction approx. US$ 100 Mn over a period of five years to enhance public education, reinforce numerous dementia initiatives being taken by various health and social service agencies, and collect and distribute data related to cognitive decline. Additionally, the increase in funding for lewy body dementia treatment has been reinforced by the novel R&D initiative by the National Institutes of Health (NIH).
Increasing prevalence of lewy body dementia and the absence of concerned drugs to manage this ailment is influencing pharma companies to invest in R&D. Currently, Alzheimer’s treatment drugs are used for managing lewy body dementia; however, it is highly likely that a range of generic drugs will proliferate the market in the near future.
The high cost of lewy body dementia treatment has prompted healthcare providers to bring certain aspects under the ambit of reimbursements. Favorable regulations pertaining to lewy body dementia treatment have meant that economically weaker sections of the society have access to quality care, which in turn has opened up opportunities for pharmaceutical companies.
The adverse effects of drugs used in lewy body dementia treatment are denting consumer and caregiver confidence, creating significant challenges for market growth. For instance, long term exposure to widely used cholinesterase inhibitors for symptomatic treatment of lewy body dementia can cause side effects, such as vomiting, diarrhea, weight loss, and insomnia. The numerous side effects associated with lewy body dementia treatment drugs have been restricting the growth of lewy body dementia treatment market. Although reimbursement policies are available in certain countries, governments in various countries are yet to offer support for lewy body treatment. Considering the high cost of lewy body dementia treatment, a significant population does not receive continuous care, leading to limited drug sales. Furthermore, lewy body dementia treatment requires long-term care, with various complications triggering the cost of treatment over time. The numerous technical, regulatory and economic constraints imposed during the development process of a drug remain a significant cost driver. 

Other players operating in the lewy body dementia treatment market and profiled in the report include BioArctic AB, Sumitomo Dainippon Pharma Co., Ltd., Jazz Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., Eli Lilly and Company, Novartis AG, Pfizer Inc., Bayer AG, Mylan NV, Sanofi AG, Teva Pharmaceuticals, GlaxoSmithKline, Eisai Co., Ltd., Takeda Pharmaceutical Company Ltd., Allergan Plc., Janssen Pharmaceuticals, Inc., Bausch Health Companies Inc., and Mallinckrodt Pharmacauticals.     

Ask Industry Experts about this Report - https://www.factmr.com/connectus/sample?flag=AE&rep_id=1154

The rise in ageing population has been gradually increasing the patient pool for lewy body dementia treatment market, with leading manufacturers working on introducing new products tailored to solely focus on lewy body dementia. Pharma companies are focusing on the development of highly innovative and competitive pipeline products. To capitalize on the changing healthcare patterns, manufacturers are diversifying their treatment offerings and business expansion via strategic tie-ups with primary care hospitals and clinics in the Asian and European countries. 

Contact Us
FactMR
11140 Rockville Pike
Suite 400, Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Read Industry News at: https://insiderstribune.com

About FactMR

FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

This release was published on openPR.